{"id":4180,"date":"2026-11-09T09:00:00","date_gmt":"2026-11-09T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4180"},"modified":"2026-11-10T21:12:47","modified_gmt":"2026-11-11T01:12:47","slug":"dual-bispecific-regimen-shows-early-prostate-cancer-activity","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4180","title":{"rendered":"Dual Bispecific Regimen Shows Early Prostate Cancer Activity"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_Pasritamig_Therapeutic_Indications-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4193\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_Pasritamig_Therapeutic_Indications-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_Pasritamig_Therapeutic_Indications-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_Pasritamig_Therapeutic_Indications-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Johnson_and_Johnson_Pasritamig_Therapeutic_Indications.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Johnson &amp; Johnson<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Phase 1 data (SITC late-breaking)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>T-cell engager plus costimulatory bispecific<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Pasritamig plus JNJ-9401<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>KLK2\u00d7CD3; PSMA\u00d7CD28<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Metastatic castration-resistant prostate cancer<\/p>\n<h4>Summary<\/h4>\n<p>Recovered source-gap item: Johnson &amp; Johnson disclosed November 9 Phase 1 activity for pasritamig plus JNJ-9401 in metastatic castration-resistant prostate cancer. At the recommended regimen, 11 of 15 patients achieved a PSA decline of at least 50%. The small uncontrolled biomarker cohort cannot establish survival benefit.<\/p>\n<p>The SITC late-breaking analysis reported PSA90 in 7 of 15; all seven remained on treatment beyond six months without progression at the described cutoff. No grade 3 or higher treatment-related events were reported in this early analysis. The regimen combines a KLK2\u00d7CD3 T-cell engager with a PSMA\u00d7CD28 costimulatory bispecific, administered every six weeks after step-up dosing. An ongoing Phase 3 trial tests addition of JNJ-9401 to pasritamig.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> tumor-localized costimulation on a second prostate antigen may deepen and sustain T-cell engagement. The biomarker response depth and regimen design support testing. Counterargument: 15 patients, no randomized comparator and PSA as a surrogate limit inference about radiographic or survival benefit.<\/p>\n<p><strong>Interpretation B:<\/strong> CD28 costimulation could add cytokine or off-tissue toxicity as exposure broadens. No severe related events in this cohort tempers but does not refute that risk. Randomized radiographic PFS and OS, antigen profiling, cytokine\/CRS tables and durability will discriminate and could falsify the dual-antigen advantage.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>J&amp;J develops investigational pasritamig, a KLK2\u00d7CD3 bispecific, and JNJ-9401, a PSMA\u00d7CD28 bispecific, for metastatic castration-resistant prostate cancer. Dual antigen targeting seeks to focus both T-cell activation and costimulation at tumor tissue.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: disclosed cohort denominators and trial identifiers.<\/li>\n<li>Company claim: outpatient feasibility and encouraging safety.<\/li>\n<li>Missing: full denominator across dose levels, objective imaging response, exact follow-up, prior-therapy distribution and comparative benefit.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A notable mechanistic human signal that justifies the ongoing randomized test; its direction for patients remains provisional.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 3 of 5. Signal Direction: cautiously positive for biomarker activity, uncertain for clinical benefit-risk. Confidence in Facts: high for reported numbers. Confidence in Interpretation: low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recovered source-gap item: Johnson &#038; Johnson disclosed November 9 Phase 1 activity for pasritamig plus JNJ-9401 in metastatic castration-resistant prostate cancer. At the recommended regimen, 11 of 15 patients achieved a PSA decline of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4193,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[79,1420,262],"class_list":["post-4180","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-johnson-johnson","tag-pasritamig","tag-prostate-cancer"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4180"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4180\/revisions"}],"predecessor-version":[{"id":4201,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4180\/revisions\/4201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4193"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}